Seer, Inc.
No enriched coverage for $SEER in the last 7 days.
No SEC Form 4 filings for $SEER in the last 30 days.
The company aims to uncover molecular and cellular signatures associated with disease onset, progression, and risk, often before clinical symptoms appear.
Scientific presentations reveal how Seer's Proteograph Product Suite is a critical component of multi-omic translational studies and enables profiling of protein isoform-specific biomarkers Scientific presentations reveal how Seer's Proteograph Product Suite is a critical component of multi-omic ...
REDWOOD CITY, Calif., Oct. 10, 2025 ( GLOBE NEWSWIRE ) -- Seer, Inc. ( NASDAQ:SEER ) , the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation at the upcoming American Society of Human Genetics ( ASHG ) 2025 Annual Meeting, taking place October ...
